Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 3, 2006, Pages 531-536

  Shiah, Her Shyong ^a   Cheng, Ann Lii ^b   Hsu, Chiun ^b   Hsu, Chih Hung ^b   Liu, Tsang Wu ^a   Chang, Jang Yang ^a   Jan, Chang Ming ^d   Chao, Yee ^c   Yu, Wei Lan ^a   Chuang, Tsai Rong ^a   Whang Peng, Jacqueline ^a   Chen, Li Tzong ^a,c,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

5 fluorouracil; Gemcitabine; High dose; Leucovorin; Pancreatic cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; KAOLIN; LOPERAMIDE; PECTIN; SEROTONIN ANTAGONIST; TANNIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANALYTIC METHOD; ANEMIA; ARTICLE; BLEEDING; BLURRED VISION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HAND PARESTHESIA; HAND TREMOR; HEMATOLOGIC DISEASE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; TOXICITY;

EID: 33645033691     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03957.x     Document Type: Article

References (26)

1. Li D Xie K Wolff R et al. Pancreatic cancer Lancet 2004 363 1049 57
2. Berlin JD Rothenberg ML Chemotherapeutic advances in pancreatic cancer CurrOncolRep 2003 5 219 26
3. Heinemann V Xu YZ Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine MolPharmacol 1990 38 567 72
4. Heinemann V Xu YZ Chubb S et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation Cancer Res 1992 52 533 9
5. Burris HA III. Moore MJ Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial JClinOncol 1997 15 2403 13
6. Rothenberg ML Moore MJ Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer AnnOncol 1996 7 347 53
7. Spears CP Gustavsson BG Mitchell MS et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil Cancer Res 1984 44 4144 50
8. Ardalan B Chua L Tian EM et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma JClinOncol 1991 9 625 30
9. Muggia FM Moran RG Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea SeminOncol 1992 19 90 3
10. O'Dwyer PJ Paul AR Walczak J et al. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer JClinOncol 1990 8 1497 503
11. Bruckner HW Zhou G Haenel P et al. Ex vivo ATP tumor testing of gemcitabine for combination chemotherapy and biochemical modulation (abstract) ProcAmAssocCancer Res 1998 89 310
12. O'Dwyer PJ Manola J Valone FH et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-1-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule: an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study JClinOncol 2001 19 2413 21
13. Chen LT Whang-Peng J Current status of clinical studies for colorectal cancer in Taiwan ClinColorectal Cancer 2004 4 196 203
14. Chen LT Liu TW Wu CW et al. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer Oncology 2002 63 239 47
15. Miller AB Hoogstraten B Staquet M et al. Reporting results of cancer treatment Cancer 1981 47 207 14
16. Kaplan EL Meier P Nonparametric estimation from incomplete observations JAmStatAssoc 1958 53 457 81
17. Abbruzzese JL Grunewald R Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine JClinOncol 1991 9 491 8
18. Carmichael J Fink U Russell RC et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer BrJCancer 1996 73 101 5
19. Hidalgo M Castellano D Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer JClinOncol 1999 17 585 92
20. Heinemann V Present and future treatment of pancreatic cancer SeminOncol 2002 29 23 31
21. Barone C Cassano A Corsi DC et al. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study Oncology 2003 64 139 45
22. Correale P Messinese S Marsili S et al. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid BrJCancer 2003 89 239 42
23. Oliani C Padovani M Manno P et al. Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study Anticancer Res 2004 24 2107 12
24. Berlin JD Catalano P Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 JClinOncol 2002 20 3270 5
25. Di Costanzo F Sdrobolini A Carlini P et al. Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic cancer: a GOIRC randomized phase II trial (Abstract) ProcAmSocClinOncol 2001 20 154a
26. Wu WC Chen SC Su YC et al. Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin JGastroenterolHepatol 2004 19 716 17